- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03044977
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
Phase 1 Trial Using 131I MIBG and 90Y DOTATOC in a Dosimetrically Determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors.
Study Overview
Status
Intervention / Treatment
Detailed Description
[131]Iodine-MIBG and [90]Yttrium-DOTATOC are radioactive drugs designed to treat specific tumor cells. These drugs are a combination of the radiation (131-Iodine, 90-Yttrium) and a protein that targets the tumor cell (MIBG or DOTATOC). Because these proteins are attracted to, and stick to, the tumor, the radiation is centered in the tumors. This kills more tumor cells and minimizes radiation-damage to healthy tissues, like the heart and lungs.
Two organs still absorb some of the radiation, though: bone marrow and the kidney. These organs limit how much radiation can be given to tumors, but we don't know how much radiation is too much. Too much radiation to bone marrow can result in anemia. Too much radiation to the kidneys can result in kidney failure. From prior radiation therapies, we have a general idea of how much radiation we can give safely.
131I-MIBG and 90Y-DOTATOC have never been given together. We want to give them together because many times, tumors are actually groups of different types of cells. This means, not all the cells respond to therapy the same way. If some tumor cells survive therapy, the tumor will continue to grow and eventually come back. We know some mid-gut neuroendocrine tumors (NETs) have targets for DOTATOC and some other mid-gut NETs have targets for MIBG. We also have now identified that some people with mid-gut NETs have different tumors: some with targets for MIBG and some with targets for DOTATOC. For these people, this means treating only with 131I-MIBG or 90Y-DOTATOC will not be enough to treat their cancer. They need both radioactive drugs.
Because we are combining these radioactive drugs, this study is known as a first-in-man study. We are also using a special imaging to help us estimate the radiation dose to the bone marrow and to the kidneys. This is what decides the final dose of 131I-MIBG and 90Y-DOTATOC.
Before receiving therapy, participants will be asked to undergo imaging to verify they have both MIBG and DOTATOC tumor types:
- participants are given very small doses of radioactive drugs
- a special camera (SPECT/CT) collects images (scans)
- imaging (scans) are done over 3 calendar days
- blood samples are taken at that time, too, to measure the circulating amount of tracer doses
If the scans show a participant has both MIBG and DOTATOC tumors, therapy is given:
- a customized dose of 90Y-DOTATOC is given on day 1 of a treatment cycle. This is given outpatient.
- a customized dose of 131I-MIBG is given on day 2 of a treatment cycle. This is given inpatient (admitted to the hospital).
- participants are monitored through blood tests to identify the side effects of therapy.
Each participant can have up to 2 cycles of therapy. The cycles are 12 weeks apart.
The doses for 90Y-DOTATOC and 131I-MIBG are decided based on radiation to the bone marrow and radiation to the kidney. Doses are decided by how well other participants have done on this study.
Participants have life long follow-up for this study. This is very important, because a study like this has not been done.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Holden Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
A 2-step eligibility is utilized for this study.
STEP 1:
Inclusion Criteria:
- Ability to understand and the willingness to provide informed consent.
- A pathologically confirmed (histology or cytology) malignant neoplasm that is determined to be well-differentiated neuroendocrine tumor (i.e. grade 1 or grade 2). The primary tumor location should be known or believed to be midgut, or pheochromocytoma, or paraganglioma.
- Disease not amenable to curative intent treatment (primarily surgery) and in addition has shown either clinical or radiographic progression on all available (non-radionuclidic) therapies known to confer clinical benefit.
- SSTR positive sites as demonstrated by either SSTR2 positivity (2+ or 3+ intensity and greater than 10% tumor cell occupying the receptors) or a nuclear medicine scan utilizing 111In-DTPA-Phe3-Octreotide (Octreoscan™) or 68Ga-DOTA-tyr3-Octreotide within 12 months prior to anticipated C1D1 demonstrating SSTR positive tumor sites
- ≥1 tumor site must have demonstrated uptake equal to or greater than normal liver as documented by nuclear scan imaging
- ≥1 evaluable site of disease measuring ≥ 1.5 cm in diameter on CT or MRI as measured per RECIST
- ≥ 18 to 70 years at the time of study drug administration.
- Karnofsky Performance Status at least 70%
- Agrees to contraception.
Exclusion criteria:
- Patients who are considered a fall risk.
- Women who are pregnant or breast feeding.
- Surgery, radiation or chemotherapy within 4 weeks of proposed step 1 start date.
- Prior peptide-receptor radiotherapy (PRRT).
- Investigational drug within 4 weeks of proposed step 1 start date.
- More than one concurrent, malignant disease.
- History of congestive heart failure and cardiac ejection fraction ≤ 40%.
- Patients for whom, in the opinion of their physician, a 24-hour discontinuation of somatostatin analogue therapy represents a health risk.
- Patients who are unable to discontinue medications known to affect MIBG uptake
- Proteinuria, grade 2 (i.e., ≥ 2+proteinuria).
- Long-acting somatostatin analogue treatment within 14 days of proposed step 1 start date.
- Prior external beam radiation involving kidneys (scatter doses of < 500 cGy to a single kidney or radiation to < 50% of a single kidney is acceptable).
- Prior external beam radiation (including brachytherapy) involving 25% of bone marrow (excluding scatter doses of ≤ 5 Gy).
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to 90Y-DOTA-tyr3-Octreotide, Octreoscan®, 68Ga-Octreotide, or 131I-MIBG.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
If a subject meets STEP 1 criteria, a serial SPECT scan is performed for dosimetry. Step 2 criteria must be met and verified prior to therapy initiation.
STEP 2:
Inclusion Criteria:
Subjects must demonstrate at least one of the following:
- One or more MIBG+ and DOTATOC- tumors in addition to one or more DOTATOC+ tumors, and/or,
- One or more tumor sites where the calculated "safe" radiation tumor dose is higher by at least 25% with a combination of 131I-MIBG and 90Y-DOTATOC than it is with 90Y DOTATOC alone, or,
Within 2 weeks of study drug administration for therapeutic intent, patients must have normal organ and marrow function as defined below:
- absolute neutrophil count ≥ 2000 cells/mm3
- platelets ≥100,000 cells/mm3
- total bilirubin <1.5 x institutional ULN for age and weight
- AST(SGOT) ≤ 2.5 x institutional ULN
- ALT (SGPT) ≤ 2.5 x institutional ULN
- eGFR ≥ 50 mL/min/1.73 m2 (Cockroft Gault formula)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
This is the initial treatment arm. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart. Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy) |
Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide.
For intravenous administration only.
Other Names:
Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide.
For intravenous administration only.
|
Experimental: Cohort 2
This treatment arm is opened if Cohort 1 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart. Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy) |
Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide.
For intravenous administration only.
Other Names:
Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide.
For intravenous administration only.
|
Experimental: Cohort 3
This treatment arm is opened if Cohort 2 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart. Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy) |
Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide.
For intravenous administration only.
Other Names:
Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide.
For intravenous administration only.
|
Experimental: Cohort -1 (alternative cohort)
This treatment arm is opened if Cohort 1 is not tolerated. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart. Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy) No further dose evaluations are done after this cohort is completed. |
Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide.
For intravenous administration only.
Other Names:
Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide.
For intravenous administration only.
|
Experimental: Cohort 2.1 (renal alternative)
This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart. Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy) No further dose evaluations are done after this cohort is completed. |
Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide.
For intravenous administration only.
Other Names:
Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide.
For intravenous administration only.
|
Experimental: Cohort 2.2 (bone marrow alternative)
This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart. Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy) No further dose evaluations are done after this cohort is completed. |
Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide.
For intravenous administration only.
Other Names:
Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide.
For intravenous administration only.
|
Experimental: Cohort 3.1 (renal alternative)
This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 3. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart. Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy) No further dose evaluations are done after this cohort is completed. |
Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide.
For intravenous administration only.
Other Names:
Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide.
For intravenous administration only.
|
Experimental: Cohort 3.2 (bone marrow alternative)
This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart. Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy) No further dose evaluations are done after this cohort is completed. |
Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide.
For intravenous administration only.
Other Names:
Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide.
For intravenous administration only.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
glomular filtration rate (eGFR)
Time Frame: 4 and 8 weeks after each treatment, then at 3, 6, & 9 months after the last treatment
|
Evaluate renal toxicity using eGFR measurement
|
4 and 8 weeks after each treatment, then at 3, 6, & 9 months after the last treatment
|
urine protein
Time Frame: Monthly beginning 4 weeks after the first treatment through 6 months after the last treatment
|
Evaluate renal toxicity using urine protein measurement
|
Monthly beginning 4 weeks after the first treatment through 6 months after the last treatment
|
platelet count decreased
Time Frame: Weeks 4, 5, 6, 7, 8 after each therapy and then 3, 6, & 12 months after the last treatment
|
Evaluate bone marrow toxicity using platelet counts
|
Weeks 4, 5, 6, 7, 8 after each therapy and then 3, 6, & 12 months after the last treatment
|
absolute neutrophil count decreased
Time Frame: Weeks 4, 5, 6, 7, 8 after each therapy and then 3, 6, & 12 months after the last treatment
|
Evaluate bone marrow toxicity using absolute neutrophil count
|
Weeks 4, 5, 6, 7, 8 after each therapy and then 3, 6, & 12 months after the last treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: Every 6 months for up to 5 years
|
From day 1 of therapy to documented disease progression in CT or MRI as per RECIST criteria
|
Every 6 months for up to 5 years
|
Overall survival (OS)
Time Frame: Up to 5 years
|
From start of treatment (cycle 1, day 1) until the date of death from any cause.
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: David Bushnell, MD, University of Iowa
Publications and helpful links
General Publications
- Madsen MT, Bushnell DL, Juweid ME, Menda Y, O'Dorisio MS, O'Dorisio T, Besse IM. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. J Nucl Med. 2006 Apr;47(4):660-7.
- Bushnell DL, Madsen MT, O'cdorisio T, Menda Y, Muzahir S, Ryan R, O'dorisio MS. Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI Res. 2014 Dec;4(1):38. doi: 10.1186/s13550-014-0038-2. Epub 2014 Sep 10.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201608857
- P50CA174521-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
-
Catholic University of the Sacred HeartCompletedNeuroendocrine Tumors | Neuroendocrine Carcinoma | Pancreas Neoplasm | Neuroendocrine Tumor Gastrointestinal, Hormone-SecretingItaly
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Digestive System Neuroendocrine Tumor G1 | Metastatic Carcinoid Tumor | Recurrent Digestive System Neuroendocrine Tumor G1 | Regional Digestive System Neuroendocrine Tumor G1 | Midgut Neuroendocrine Tumor G1 | Foregut Neuroendocrine Tumor | Hindgut Neuroendocrine Tumor | Neuroendocrine...Canada, United States
-
University of WashingtonEli Lilly and CompanyRecruitingLocally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Metastatic Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine Tumor | Advanced Digestive System Neuroendocrine Neoplasm | Digestive System Neuroendocrine Tumor | Foregut Neuroendocrine Tumor | Hindgut Neuroendocrine... and other conditionsUnited States
-
Viewpoint Molecular TargetingRecruitingNeuroendocrine Tumors | Pheochromocytoma | Carcinoid Tumor | Paraganglioma | Neuroendocrine Tumor of the Lung | Neuroendocrine Carcinoma Metastatic | Neuroendocrine Tumor of Pancreas | Neuroendocrine Tumor Carcinoid | Carcinoid Tumor of GI SystemUnited States
-
National Cancer Institute (NCI)Active, not recruitingCarcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterRecruitingMetastatic Digestive System Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Digestive System Neuroendocrine Tumor G1 | Digestive System Neuroendocrine Tumor G2United States
-
Aadi Bioscience, Inc.RecruitingNeuroendocrine Tumors | Pancreatic Neuroendocrine Tumor | Gastrointestinal Neuroendocrine Tumor | NET | Pulmonary Neuroendocrine TumorUnited States
-
National Cancer Institute (NCI)CompletedMetastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Pulmonary Carcinoid TumorCanada
-
National Cancer Institute (NCI)CompletedLung Carcinoid Tumor | Metastatic Digestive System Neuroendocrine Tumor G1 | Pancreatic Polypeptide Tumor | Multiple Endocrine Neoplasia Type 1 | Pancreatic Glucagonoma | Pancreatic Insulinoma | Somatostatin-Producing Neuroendocrine Tumor | Recurrent Digestive System Neuroendocrine Tumor G1 | Recurrent... and other conditionsUnited States
-
University of Michigan Rogel Cancer CenterNot yet recruitingPancreatic Adenocarcinoma | Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Carcinoma | Adenosquamous Carcinoma | Gastrointestinal Neuroendocrine Tumor | Gastrointestinal Neuroendocrine Carcinoma | Neuroendocrine Prostate Carcinoma
Clinical Trials on 90Y-DOTA-3-Tyr-Octreotide
-
Sue O'DorisioNational Cancer Institute (NCI); National Institutes of Health (NIH)WithdrawnMedulloblastoma | Neuroblastoma | Meningioma | Neuroendrocrine Tumors
-
Sandeep LaroiaNational Cancer Institute (NCI); National Institutes of Health (NIH); Holden...TerminatedNeuroendocrine TumorsUnited States
-
French Innovative Leukemia OrganisationTerminated
-
O'Dorisio, M SNational Cancer Institute (NCI)CompletedSarcoma | Unspecified Childhood Solid Tumor, Protocol Specific | Brain and Central Nervous System Tumors | Neuroblastoma | Pheochromocytoma | Islet Cell Tumor | Gastrointestinal Carcinoid TumorUnited States
-
Peking Union Medical College HospitalUnknown
-
University of IowaNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedNeuroendocrine Tumors | Medulloblastoma | Neuroblastoma | MeningiomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedMeningioma | Neuroendocrine Neoplasm | Multiple Endocrine Neoplasia Type 1 | Von Hippel-Lindau Syndrome | Metastatic Well Differentiated Neuroendocrine Neoplasm | Somatostatin Positive Neoplastic Cells PresentUnited States
-
AHS Cancer Control AlbertaRecruiting
-
Ludwig Institute for Cancer ResearchMemorial Sloan Kettering Cancer CenterCompletedKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Kidney NeoplasmUnited States
-
Thomas HopeCompletedNeuroendocrine TumorUnited States